DKNG vs GENI: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: GENI is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. DKNG and GENI share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined DKNG and GENI exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

DraftKings operates one of the largest US online sports betting (OSB) and iGaming platforms, alongside a daily fantasy sports business, a former retail-lottery courier operation, and a growing prediction-markets product (Pick6). Revenue comes primarily from the Sportsbook (hold on wagering handle) and iGaming (online casino), with the company live in dozens of US states plus Ontario. It sits in a consolidated duopoly with FanDuel (Flutter), with the two names controlling roughly three-quarters or more of US gross gaming revenue.

Full DKNG guide

Genius Sports Limited is a sports data and technology company incorporated in Guernsey, headquartered in London, and listed on the New York Stock Exchange since its 2021 SPAC combination. The model has three linked parts. It signs exclusive rights with leagues and federations to collect their official real-time data, it distributes that data plus trading and streaming products to regulated sportsbooks, and it supplies technology back to the leagues themselves, which is often how the rights get paid for. Its anchor asset is the NFL, where Genius is the exclusive distributor of official data feeds and operates BetVision, the low-latency watch-and-bet product embedded inside sportsbook apps. That partnership was extended and widened and now runs through the end of the 2029 NFL season, and it lets Genius monetise advertising inventory against the BetVision streams. Beyond the NFL, the rights portfolio spans several hundred competitions including English football and FIBA basketball.

Full GENI guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• DKNG drivers: Duopoly scale and structural profitability; New-state and iGaming expansion.
• GENI drivers: The NFL contract and BetVision; Legend and the pivot into owned media.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Valuation is the central risk: the stock trades at a very high multiple of trailing GAAP earnings (which remain minimal), so disappointment on margin or growth can drive sharp drawdowns. For GENI, the dominant structural risk is rights renewal: Genius does not own the sports, it rents them, and every renewal is an auction that Sportradar and others can bid up until the contract stops being profitable.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick DKNG if you believe its drivers more; GENI if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the DKNG and GENI guides.

DKNG. DraftKings is valued on scale and future profitability rather than current earnings, so its trailing P/E is extreme and near-meaningless. The more relevant frame is revenue growth (mid-teens percent) converting into a rising adjusted EBITDA margin as states mature. Guidance and quarterly hold percentages tend to move the stock more than reported net income.

GENI. At roughly $2.33 billion the market cap is about 2.9x trailing revenue and roughly 2.3x the midpoint of guided 2026 revenue, or about 8x guided adjusted EBITDA before adjusting for the debt raised to fund Legend. That is a growth multiple rather than a value one, and it is being paid on an adjusted figure while GAAP results are still loss-making. Figures are approximate and tied to the asOf date, so check live numbers and the latest 6-K before drawing conclusions.

Headline figures (approximate, JULY 2026): DKNG shows revenue (ttm) ~$6.0-6.3B, q1 2026 revenue ~$1.65B (up ~17% YoY), fy2026 revenue guidance ~$6.5-6.9B, fy2026 adj. ebitda guidance ~$700-900M; GENI shows revenue (ttm) ~$790 million, q2 2026 revenue ~$196 million, up ~65% year over year and ahead of ~$185 million guided, q2 2026 adjusted ebitda ~$53 million against ~$45 million guided, fy2026 guidance (raised) ~$1.005 billion to ~$1.025 billion revenue, ~$285 million to ~$295 million adjusted EBITDA (~28.6% margin at midpoint).

DKNG and GENI are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined DKNG and GENI exposure against your real portfolio. It is not an investment adviser.